Human pharmacological MRI

Trends in Pharmacological Sciences

Volumn 25, Issue 7, 2004, Pages 366-374

  Honey, Garry ^a   Bullmore, Ed ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FLUMAZENIL; HALOPERIDOL; KETAMINE; LORAZEPAM; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORADRENALIN; PAROXETINE; PHYSOSTIGMINE; RISPERIDONE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; UNINDEXED DRUG;

ADDICTION; BRAIN; COGNITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR DEPRESSION; NEUROPSYCHIATRY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER AGENTS;

EID: 3042569770     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.05.009     Document Type: Review

References (59)

1. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 21:2000;314-318
2. Chen Y.C., et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 38:1997;389-398
3. Mattay V.S., et al. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage. 12:2000;268-275
4. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575
5. Egan M.F., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6917-6922
6. Mattay V.S., et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6186-6191
7. Rao S.M., et al. Effects of methylphenidate on functional MRI blood-oxygen-level-dependent contrast. Am. J. Psychiatry. 157:2000;1697-1699
8. Bullmore E., et al. Practice and difficulty evoke anatomically and pharmacologically dissociable brain activation dynamics. Cereb. Cortex. 13:2003;144-154
9. Furey M.L., et al. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science. 290:2000;2315-2319
10. Thiel C.M., et al. Effects of cholinergic enhancement on conditioning-related responses in human auditory cortex. Eur. J. Neurosci. 16:2002;2199-2206
11. Bentley P., et al. Cholinergic enhancement modulates neural correlates of selective attention and emotional processing. NeuroImage. 20:2003;58-70
12. Thiel C.M., et al. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J. Neurosci. 21:2001;6846-6852
13. Thiel C.M., et al. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study. Neuropsychopharmacology. 27:2002;282-292
14. Stephenson C.M., et al. GABAergic inhibitory mechanisms for repetition-adaptivity in large-scale brain systems. Neuroimage. 19:2003;1578-1588
15. Shaywitz S.E., et al. Persistence of dyslexia: the connecticut longitudinal study at adolescence. Pediatrics. 104:1999;1351-1359
16. Coull J.T., et al. The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb. Cortex. 11:2001;73-84
17. Honey G.D., et al. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13432-13437
18. Daniel D.G., et al. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1:1989;377-384
19. Hertel P., et al. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl.). 124:1996;74-86
20. Stephan K.E., et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol. Med. 31:2001;1065-1078
21. Nahas Z., et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 9:2003;274-282
22. Honey G.D., et al. Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain. 126:2003;1767-1781
23. Mattay V.S., et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann. Neurol. 51:2002;156-164
24. Kalin N.H., et al. Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine. J. Clin. Psychiatry. 58:(Suppl. 16):1997;32-39
25. Davidson R.J., et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am. J. Psychiatry. 160:2003;64-75
26. Breiter H.C., et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 19:1997;591-611
27. Stein E.A., et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry. 155:1998;1009-1015
28. Wrase J., et al. Development of alcohol-associated cues and cue-induced brain activation in alcoholics. Eur. Psychiatry. 17:2002;287-291
29. Schneider F., et al. Subcortical correlates of craving in recently abstinent alcoholic patients. Am. J. Psychiatry. 158:2001;1075-1083
30. Gollub R.L., et al. Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects. J. Cereb. Blood Flow Metab. 18:1998;724-734
31. Jacobsen L.K., et al. Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magn. Reson. Imaging. 20:2002;141-145
32. Kimberg D.Y., et al. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum. Brain Mapp. 12:2001;246-257
33. Hariri A.R., et al. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology. 27:2002;1036-1040
34. Brassen S., et al. Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci. Lett. 340:2003;193-196
35. Arthurs O.J., et al. Dopaminergic effects on electrophysiological and functional MRI measures of human cortical stimulus-response power laws. NeuroImage. 21:2004;540-546
36. Sperling R., et al. Functional MRI detection of pharmacologically induced memory impairment. Proc. Natl. Acad. Sci. U. S. A. 99:2002;455-460
37. Thiel C.M., et al. Cholinergic modulation of experience-dependent plasticity in human auditory cortex. Neuron. 35:2002;567-574
38. Bentley P., et al. Effects of attention and emotion on repetition priming and their modulation by cholinergic enhancement. J. Neurophysiol. 90:2003;1171-1181
39. Northoff G., et al. GABA-ergic modulation of prefrontal spatio-temporal activation pattern during emotional processing: a combined fMRI/MEG study with placebo and lorazepam. J. Cogn. Neurosci. 14:2002;348-370
40. Abel K.M., et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. NeuroReport. 14:2003;387-391
41. Loubinoux I., et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage. 15:2002;26-36
42. Muller J.L., et al. Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;421-426
43. Tessitore A., et al. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. J. Neurosci. 22:2002;9099-9103
44. Buhmann C., et al. Pharmacologically modulated fMRI-cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain. 126:2003;451-461
45. Peters S., et al. Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients. NeuroReport. 14:2003;809-812
46. Sheline Y.I., et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry. 50:2001;651-658
47. Vaidya C.J., et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14494-14499
48. Anderson C.M., et al. Effects of methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in boys with ADHD. Am. J. Psychiatry. 159:2002;1322-1328
49. Pariente J., et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann. Neurol. 50:2001;718-729
50. Jokeit H., et al. Carbamazepine reduces memory induced activation of mesial temporal lobe structures: a pharmacological fMRI-study. BMC Neurol. 1:2001;6
51. Wise R.G., et al. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. NeuroImage. 16:2002;999-1014
52. Sell L.A., et al. Functional magnetic resonance imaging of the acute effect of intravenous heroin administration on visual activation in long-term heroin addicts: results from a feasibility study. Drug Alcohol Depend. 49:1997;55-60
53. Li S.J., et al. Cocaine administration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI. Magn. Reson. Med. 43:2000;45-51
54. Lawrence N.S., et al. Cognitive mechanisms of nicotine on visual attention. Neuron. 36:2002;539-548
55. Levin J.M., et al. Reduction in BOLD fMRI response to primary visual stimulation following alcohol ingestion. Psychiatry Res. 82:1998;135-146
56. Seifritz E., et al. Effect of ethanol on BOLD response to acoustic stimulation: implications for neuropharmacological fMRI. Psychiatry Res. 99:2000;1-13
57. Laurienti P.J., et al. Dietary caffeine consumption modulates fMRI measures. NeuroImage. 17:2002;751-757
58. Mulderink T.A., et al. On the use of caffeine as a contrast booster for BOLD fMRI studies. NeuroImage. 15:2002;37-44
59. Wilkinson D., Halligan P. Opinion: The relevance of behavioural measures for functional-imaging studies of cognition. Nat. Rev. Neurosci. 5:2004;67-73